
LeMaitre Vascular (LMAT) Stock Forecast & Price Target
LeMaitre Vascular (LMAT) Analyst Ratings
Bulls say
LeMaitre Vascular is experiencing strong financial growth with double-digit organic revenue growth and favorable gross margins. They have a solid outlook for the fiscal year, including international expansion and the potential for larger deals. Additionally, the company's strong financial metrics and high cash position make them an attractive investment option with a raised stock price target and increased quarterly dividend.
Bears say
LeMaitre Vascular is seeing strong top-line growth in key product categories such as grafts, valvulotomes, and carotid shunts. The company's international commercial launch of Artegraft has also contributed to a 36% growth in this product. Despite the possibility of short-term weakness in the stock, the company's consistent double-digit organic top line growth, margin expansion, and strong cash flow justify a premium valuation and we maintain an OUTPERFORM rating with a price target of $120 due to the projected net cash position of $275 million in the next 12 months.
This aggregate rating is based on analysts' research of LeMaitre Vascular and is not a guaranteed prediction by Public.com or investment advice.
LeMaitre Vascular (LMAT) Analyst Forecast & Price Prediction
Start investing in LeMaitre Vascular (LMAT)
Order type
Buy in
Order amount
Est. shares
0 shares